INVO FERTILITY INC
IVFNASDAQTrading Snapshot
- Day Range
- $0.92 – $0.93
- 52-Week Range
- $0.90 – $84.40
- Volume
- $3.58B
- Avg Volume
- $4.65B
- Shares Outstanding
- 1.8M
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $2M
- P/E Ratio
- -0.0
- P/S Ratio
- 0.2x
- EPS (TTM)
- $-2.51
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +15530.8%
Why Investors Own IVF
- ✓High-growth profile — revenue up +55.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 77% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
INVO FERTILITY INC
IVF
StockOtter · stockotter.spaceAbout INVO FERTILITY INC
INVO Fertility, Inc. is a profitable enterprise primarily focused on delivering fertility services. Beyond this core business, the company actively develops clinical-stage therapies targeting oncology and autoimmune disorders. The firm was established on January 5, 2007, and its operations are based in Sarasota, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference
SARASOTA, Fla., Sept. 25, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertil
Financial Analysis: INVO Fertility (NASDAQ:IVF) vs. P3 Health Partners (NASDAQ:PIIIW)
P3 Health Partners (NASDAQ: PIIIW - Get Free Report) and INVO Fertility (NASDAQ: IVF - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the st
INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET
INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International
SARASOTA, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertili
INVO Fertility Stock Surges Following Q2 Earnings Beat
Shares of INVO Fertility Inc. (NASDAQ:IVF) are surging Monday afternoon after the healthcare fertility company reported second-quarter financial results that significantly outperformed Wall Street expectations on bottom-
INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability
Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices Clinic platform was profitable on an Adjusted EBITDA basis befor